Vaccine · Boston area, MA
Vaccine studies in Boston area, MA
13 recruiting studies have a site in the Boston area. This page includes nearby cities such as Cambridge, Brookline, Newton, Waltham.
13 recruiting studiesSource: ClinicalTrials.gov, refreshed October 26, 2026How we list studies
Studies
- RecruitingHealthy volunteersPhase 1/Phase 2
Phase 1/2 Study of Respiratory Syncytial Virus and Human Metapneumovirus (RSV+HMPV) Vaccine Candidate in Adults 60 Years of Age and Older
Sanofi
- Location
- Boston, MA + 49 other US sites
- Eligibility basics
- Ages 60+
- RecruitingHealthy volunteersPhase 1
A Vaccine (CMV-MVA Triplex Vaccine) for the Enhancement of CMV-Specific Immunity and the Prevention of CMV Viremia in Patients Undergoing Haploidentical Hematopoietic Stem Cell Transplant
City of Hope Medical Center
- Location
- Boston, MA + 2 other US sites
- Eligibility basics
- Ages 18–75
- RecruitingHealthy volunteersPhase 1
A Safety and Immunogenicity Trial of OCU500, ChAd36 Vector Encoding SARS-CoV-2 Spike Vaccine Via Intranasal and Inhalational Routes in Previously Vaccinated Adults
National Institute of Allergy and Infectious Diseases (NIAID)
- Location
- Boston, MA + 4 other US sites
- Eligibility basics
- Ages 18–64
- RecruitingHealthy volunteersPhase 1
Phase 1 Study of CH505 HIV Vaccine Nanoparticles and mRNA Boosters in Healthy Adults
National Institute of Allergy and Infectious Diseases (NIAID)
- Location
- Boston, MA + 1 other US site
- Eligibility basics
- Ages 18–55
- RecruitingHealthy volunteersPhase 1
A Clinical Study to Investigate the Safety and Immunogenicity of rVSV∆G-SUDV-GP, a Sudan Virus (SUDV) Vaccine for the Prevention of SUDV Disease in Adults in Good General Health
International AIDS Vaccine Initiative
- Location
- Boston, MA + 2 other US sites
- Eligibility basics
- Ages 18–50
- RecruitingHealthy volunteersPhase 1
Clinical Trial to Evaluate the Safety and Immunogenicity of the V2 Apex-Directed Immunogens DV201P-RNA and DV202B1-RNA in Adult Participants Without HIV
National Institute of Allergy and Infectious Diseases (NIAID)
- Location
- Boston, MA + 6 other US sites
- Eligibility basics
- Ages 18–55
- RecruitingHealthy volunteersPhase 3
A Phase 3 Study of Revaccination in Subsequent Pregnancies With Bivalent RSV Vaccine and Duration of Protection of a Single Dose
Pfizer
- Location
- Boston, MA + 76 other US sites
- Eligibility basics
- Ages 0 mo+
- RecruitingHealthy volunteersPhase 3
BEATRIX: A Study to Learn About a Group B Streptococcus Vaccine in Healthy Pregnant Women and Their Babies
Pfizer
- Location
- Boston, MA + 111 other US sites
- Eligibility basics
- Ages 0 mo–49
- RecruitingHealthy volunteersPhase 3
A Study on the Efficacy of a Vaccine Against Influenza in Adults ≥65 Years of Age
GlaxoSmithKline
- Location
- Boston, MA + 130 other US sites
- Eligibility basics
- Ages 65+
- RecruitingHealthy volunteersPhase 3
A Study to Learn About the Safety, Tolerability, and Immunogenicity of a Fifth Dose of 6-Valent OspA-Based Lyme Disease Vaccine
Pfizer
- Location
- Worcester, MA + 10 other US sites
- Eligibility basics
- Ages 7+
- RecruitingPhase 1/Phase 2
Study to Evaluate Safety, Efficacy and Immunogenicity of Acne mRNA Vaccine in Adults With Moderate to Severe Acne
Sanofi Pasteur, a Sanofi Company
- Location
- Brighton, MA + 78 other US sites
- Eligibility basics
- Ages 18–45
- RecruitingHealthy volunteersPhase 2
CMV-MVA Triplex Vaccination in HLA-Matched Related Stem Cell Donors for the Prevention of CMV Infection in Patients Undergoing Hematopoietic Stem Cell Transplant
City of Hope Medical Center
- Location
- Boston, MA + 2 other US sites
- Eligibility basics
- Ages 18–75
- RecruitingHealthy volunteers
ARISe at UMass Chan
University of Massachusetts, Worcester
- Location
- Worcester, MA
- Eligibility basics
- Ages 18+
Who these studies look for
Vaccine studies often exclude people who recently received a related vaccine or had the infection, and those with conditions or medicines that affect the immune system.
Matching a page like this one never means you qualify. Each research team decides eligibility at screening.